Reeves W G, Barr D, Douglas C A, Gelsthorpe K, Hanning I, Skene A, Wells L, Wilson R M, Tattersall R B
Diabetologia. 1984 Apr;26(4):266-71. doi: 10.1007/BF00283648.
Seventy-nine patients were observed prospectively during their initial period of treatment with conventional bovine insulins. Insulin antibody levels 6 months after starting insulin therapy did not correlate with age, gender or beta cell function at onset of treatment. Patients who required soluble insulin in addition to isophane insulin developed higher levels of insulin antibody. Patients bearing the HLA-B8, DR3 and C4AQO alleles had lower levels of insulin antibody, whereas those bearing DR7 produced significantly higher levels. Other alleles at the C4A, C4B, C2, factor B or Gm loci did not appear to have a significant effect on insulin antibody production. The hyporesponsiveness of B8/DR3/ C4AQO -positive individuals probably reflects a non-specific abnormality of immunity whereas the enhanced responsiveness of those positive for DR7 suggests the presence of a specific immune response gene for insulin.
对79例患者在使用常规牛胰岛素进行初始治疗期间进行了前瞻性观察。开始胰岛素治疗6个月后的胰岛素抗体水平与治疗开始时的年龄、性别或β细胞功能无关。除低精蛋白胰岛素外还需要可溶性胰岛素的患者产生的胰岛素抗体水平更高。携带HLA - B8、DR3和C4AQO等位基因的患者胰岛素抗体水平较低,而携带DR7的患者产生的胰岛素抗体水平显著更高。C4A、C4B、C2、因子B或Gm位点的其他等位基因似乎对胰岛素抗体产生没有显著影响。B8/DR3/C4AQO阳性个体的低反应性可能反映了免疫的非特异性异常,而DR7阳性个体的反应性增强表明存在胰岛素特异性免疫反应基因。